Agents of Change Research Symposium Program

RESEARCHagents of change

symposiumGlobal ImpactThe of

UBC Pharm Sci AlumniSeptember 26, 2014Vancouver Marriott Pinnacle Downtown Hotel

1


symposium

MESSAGE FROM THE DEAN

Welcome to Agents of Change Research Symposium: The Global Impact of UBC Pharm Sci Alumni. This is a new event for the Faculty of Pharmaceutical Sciences at UBC, and one that we hope to build on as our alumni continue to create lasting impacts the world over. At the Faculty, we define impact as a tangible and measurable benefit or change that influences the environment in which we live – economic benefits, improvements to treat-ments, policy changes, environmental improvements, driving educational change. We believe it is fundamentally important to highlight the positive impact that our Faculty has on the world, and today we are showcasing the achievements of some of our most noted and successful alumni. Collectively, our seven distinguished and honoured alumni represent what it truly means to create a positive impact. As agents of change in a world faced with serious health chal-lenges and obstacles to progress, their work, vision and passion for making a difference has led to real change. We are very proud of them and what they have accomplished. And we are very thankful and thrilled to have them - and all of you – with us on this special day.

Sincerely,

Michael Coughtrie, PhDProfessor and Dean

2


symposium

PROGRAM8-8:45 a.m.

8:45-8:50 a.m.

8:50-9:50 a.m.

9:50-10:05 a.m.

10:05-11:05 a.m.

11:05 a.m.-12:05 p.m.

12:05-1:35 p.m.

1:35-2:35 p.m.

2:35-3:35 p.m.

3:35-3:50 p.m.

3:50-4:50 p.m.

4:50-5:50 p.m.

5:50-6 p.m.

6-8 p.m.

Registration and Continental Breakfast

Opening RemarksDr. Helen BurtAssociate VP - Research & International, UBC

Presentation #1Dr. Peter JewessonConsultant, Professor and Dean Emeritus (Retired)

Coffee Break

Presentation #2Dr. Gary LopaschukDistinguished Professor of Pediatrics, University of Alberta

Presentation #3Dr. Subodh VermaCardiac Surgeon, St. Michael’s Hospital, Toronto, Associate Professor of Surgery and Pharmacology, University of Toronto, Director, Traineeship in Atherosclerosis, Canada Research Chair in Atherosclerosis

Lunch Break and Poster Session

Presentation #4Dr. Ric ProcyshynClinical Professor, Department of Psychiatry, Faculty of Medicine, UBC

Presentation #5Dr. Raj Suryanarayanan, MSc’81, PhD’85Professor and William and Mildred Peters Endowed Chair, Department of Pharmaceutics, College of Pharmacy, University of Minnesota

Coffee Break

Presentation #6Dr. Raman Venkataramanan, PhD’79Professor of Pharmaceutical Sciences and Pathology, Director of Clinical Pharmacokinetics Laboratory, University of Pittsburgh

Presentation #7Dr. Diana ChowProfessor of Pharmaceutics, Director, Institute of Drug Education and Research (IDER), College of Pharmacy, University of Houston

Closing RemarksDr. Michael CoughtrieProfessor and Dean, Faculty of Pharmaceutical Sciences, UBC

Dinner

3


symposium

PRESENTATIONSBringing Academic Pharmacy to Qatar: The Grand ExperimentDr. Peter Jewesson, BSc(Pharm)’78, PhD’86Consultant, Professor and Dean Emeritus (Retired)

Optimizing Energy Metabolism as an Approach to Treat Ischemic Heart Disease and Heart FailureDr. Gary Lopaschuk, BSc(Pharm)’78, MSc’80, PhD’83Distinguished Professor of Pediatrics, University of Alberta

Breast Cancer Genes and Cardiovascular Regulation: Common PathwaysDr. Subodh Verma, MSc ‘93, PhD’97Cardiac Surgeon, St. Michael’s Hospital, Toronto, Associate Professor of Surgery and Pharmacology, University of Toronto, Director, Traineeship in Atherosclerosis, Canada Research Chair in Atherosclerosis

Improving Mental Health Outcomes Through Understanding AntipsychoticsDr. Ric Procyshyn, PhD’94, PharmD’96Clinical Professor, Department of Psychiatry, Faculty of Medicine, UBC

Understanding Material Properties to Design Robust Pharmaceutical Dosage FormsDr. Raj Suryanarayanan, MSc’81, PhD’85Professor and William and Mildred Peters Endowed Chair, Department of Pharmaceutics, College of Pharmacy, University of Minnesota

Optimizing Dosing of Medications for First Chance in Life (Pregnancy) and Second Chance in Life (Organ Transplantation)Dr. Raman Venkataramanan, PhD’79Professor of Pharmaceutical Sciences and Pathology, Director of Clinical Pharmacokinetics Laboratory, University of Pittsburgh

Translational Research for Optimizing Therapy Using Approaches of Nanoformulation Development and Pharmacokinetic/Pharmacodynamic CorrelationDr. Diana Chow, PhD’81 Professor of Pharmaceutics, Director, Institute of Drug Education and Research (IDER), College of Pharmacy, University of Houston

1

2

3

4

5

6

7

4


symposium

SPEAKERSDr. Peter Jewesson BSc(Pharm)’78, PhD’86

Dr. Jewesson is a graduate of the University of British Columbia (UBC) in Vancouver, Canada. He completed a BSc(Pharm) in 1978, accredited Hospital Residency Program in 1979, the first Canadian PhD in Clinical Pharmacy in 1986, and the first PMAC-sponsored fellowship in 1987. He became an Assistant Professor in 1986, was tenured and promoted to Associate Professor in 1991, and to Full Professor in 1996, the first in his discipline at UBC. In 1994, he was recognized as a Fellow, Canadian Society of Hospital Pharmacists. Between 1986 and 2004, Dr. Jewesson was cross-appointed to Vancouver Hospital. He was a Co-Director (alongside his wife, Barbara) for 13 years (1991-2004). During his 18-year tenure at this large teaching institution, he was appointed to the Department of Medicine Division of Infectious Diseases, and implemented one of Canada’s first hospital drug use evaluation/optimization/cost containment programs. In collaboration with a talented team, he was responsible for implementing a clinical program, a serum drug concentra-tion consulting service, a multi-disciplinary outpatient parenteral antimicrobial therapy program, an infusion device consulting service and other initiatives aimed at improving health and economic outcomes.

Dr. Jewesson has authored over 135 peer-reviewed publications, 100 research abstracts/posters, 120 invited presentations, and he has received 17 research awards. He has taught pharmacy, nursing and medical students, and as a Residency Coordinator and Director, he has also mentored dozens of postgraduate pharmacy residents. For six years (1996-2002), he also taught and served as the Director of the Doctor of Pharmacy Program at UBC, the first program of its type in Canada.

In 2006 and on invitation of President Sheikha Al-Misnad, Dr. Jewesson and his wife Barbara travelled to Qatar to join the national university and launch the first pharmacy degree program in this progressive Middle Eastern country. Over the subsequent six years, he laid the foundation for the first international pharmacy college to ever achieve full CCAPP (Canada) accreditation status. During his tenure with Qatar University, Dean


symposium

SPEAKERSDr. Peter Jewesson BSc(Pharm)’78, PhD’86

Jewesson and his team transformed a small program into the university’s seventh college, implemented three degree programs (BSc, MSc, PharmD), assembled and mentored a team of talented and committed faculty and staff, attracted highly motivated and intellec-tually capable students, established strong partnerships with local and international affili-ates and contributed to the advancement the pharmacy education, practice and research in this region. Under his leadership, the program has achieved regional and international recognition for quality and innovation.

In 2012, Dr. Jewesson chose to retire from full-time academic life to pursue personal interests. In 2012/13, he continued to support Qatar University as a senior advisor for several major initiatives including international relations, strategic planning, accreditation and licensure, and the design and construction of the first pharmacy college building in Qatar. He is now providing consulting services for Qatar and other international clients while travelling and enjoying life as a nomad.

5

6


symposium

SPEAKERSDr. Gary Lopaschuk BSc(Pharm)’78, MSc’80, PhD’83

Dr. Gary D. Lopaschuk is a Distinguished University Professor of Pediatrics at the University of Alberta, Edmonton. He is a Cardiovascular Researcher whose research focuses on the regulation of fatty acid oxidation in the heart, and the mechanism by which high rates of fatty acid oxidation contribute to heart disease and heart failure. He is also examin-ing how alterations in fatty acid metabolism contribute to cardiovascular disease in the diabetic. At a molecular level he has characterized a number of key enzymes important in the regulation of cardiac fatty acid oxidation. He is also developing a number of thera-peutic strategies that involve optimizing energy metabolism in the heart that can be used to prevent the development of heart disease, and that can also be used to treat heart failure. His research has resulted in the publication of over 350 original research articles, and he has been recognized by awards such as the Canadian Cardiovascular Research Achievement Award and the International Academy of Cardiovascular Sciences Research Achievement Award.

Dr. Lopaschuk is an Alberta Innovates Health Solution Scientist, and is a Fellow of the Royal Society of Canada. He has served as Scientific Director of the Mazankowski Alberta Heart Institute, and has previously served in a number of capacities with the Heart and Stroke Foundation of Canada, including as Chair of the Scientific Review Committee and the Vice-Chair of the Research Planning and Priorities Committee. He serves on a number of journal editorial boards, including Circulation Research, Journal of Clinical Investigation, American Journal of Physiology, Cardiovascular Research, Journal of Molecular and Cellular Cardiology, Canadian Journal of Physiology and Pharmacology, Heart and Metabolism, and Cardiovascular Drugs and Therapy. He is also the President and CEO of a biotechnology company (Metabolic Modulators Research Ltd.), that is developing novel drugs to treat heart disease that optimize energy metabolism in the heart.

7


symposium

SPEAKERSDr. Subodh Verma MSc ‘93, PhD’97

In just over a decade and a half, Dr. Subodh Verma has staunchly established himself as an expert Canadian clinician-scientist in vascular biology, endothelial dysfunction and atherosclerosis. With a Bachelor’s degree in Pharmacy and a PhD in Cardiovascular Pharmacology, both from the University of British Columbia, Dr. Verma went on to pursue an MD degree and research fellowship in Cardiology at the University of Calgary. This was followed by FRCSC training at the University of Toronto, which has culminated in his present appointment as staff cardiac surgeon and associate professor at St. Michael’s Hospital, University of Toronto.

Dr. Verma is the recipient of numerous accolades. On the national level, his awards include a Medical Research Council fellowship (ranked 1st of 412), a Heart and Stroke Foundation fellowship, an Alberta Heritage Foundation for Medical Research fellowship, a Canadian Diabetes Association fellowship, a Physicians Services Inc. research prize for outstanding research paper, a PMAC Award, a Pfizer research prize, a Burroughs Wellcome Medical Research Council Award, a Young Clinician Scientist Award (1st prize) from the Canadian Association of Physicians of Indian Heritage, a Canadian Cardiovascular Society Young Investigator Award (1st place), the Paul Cartier Cardiac Surgery Young Investigator Award, and a Royal College of Physicians and Surgeons of Canada Research Award. At the international level, he has been honoured with an American Heart Association Young Investigator Award (1st prize in Basic Cardiovascular Sciences), the Irvine Page Award in Atherosclerosis Thrombosis and Vascular Biology (finalist), a Society of Vascular Biology and Medicine Young Investigator Award (finalist), an ISHR Young Investigator Award (1st place), two American Association for Thoracic Surgery Young Investigator Awards (finalist), a Paul Sampson Western Thoracic Society Young Investigator Award (finalist), an Interamerican Society of Cardiology Young Investigator Award, and the James T. Willerson Vul.

As of 2002, Dr. Verma’s research endeavors in the basic, translational and clinical

PRESENTED BY

8


symposium

SPEAKERSDr. Subodh Verma MSc ‘93, PhD’97

sciences have been strongly supported by the Canadian Institutes of Health Research, the Heart and Stroke Foundation and the Canadian Diabetes Association, in addition to grants from the Canadian pharmaceutical industry. Dr. Verma has published extensively (over 160 peer-reviewed papers and nearly 300 abstracts) in a wide range of basic, trans-lational and clinical science journals including The New England Journal of Medicine, Nature, and Circulation. He sits on several journal editorial boards and is a constant reviewer of more than 20 high-impact journals. Over the last five years, Dr. Verma has presented nearly 200 guest lectures within and outside of Canada and has been a visiting professor at 13 international universities.

9


symposium

SPEAKERSDr. Ric Procyshyn PhD’94, PharmD’96

Dr. Ric Procyshyn is a research psychopharmacologist at the BC Mental Health and Addictions Research Institute as well as a clinical consultant for the refractory psychosis unit at the Detwiller Pavilion, UBC. Ric holds the position of Clinical Professor in the Department of Psychiatry and Adjunct Professor in the Faculty of Pharmaceutical Sciences, both at the University of British Columbia (UBC). Along with his Doctor of Pharmacy degree, Ric possesses a PhD in Medicinal Chemistry.

Dr. Procyshyn’s research interests include smoking and schizophrenia, antipsychotic polypharmacy, antipsychotic associated metabolic disorders, mechanism of antipsy-chotic action, and drug utilization evaluations. Ric has authored several articles in peer-reviewed journals and has been invited to speak at several conferences. Dr. Procyshyn enjoys teaching and has been awarded seven teaching awards from the Faculty of Pharmaceutical Sciences at UBC.

10


symposium

SPEAKERSDr. Raj Suryanarayanan MSc’81, PhD’85

Raj Suryanarayanan (Sury) is Professor of Pharmaceutics in the College of Pharmacy, University of Minnesota. He also holds the William and Mildred Peters Endowed Chair in Pharmaceutics. He obtained his BPharm and MPharm degrees from Banaras Hindu Uni-versity, Varanasi, India and MSc and PhD degrees in Pharmaceutics from the University of British Columbia. The overall goal of his research is to apply principles of pharmaceutical materials science to the design of robust pharmaceutical dosage forms with reproducible and predictable properties. His publications in this field deal with phase transitions in solids, implications of in situ phase transitions on product performance and the prepara-tion, characterization and stabilization of amorphous pharmaceuticals. He has developed X-ray diffractometric techniques for the qualitative and quantitative analyses of solid phases to determine the drug content in intact tablets and to study solid-state reactions.

Dr. Suryanarayanan’s research group has also developed low temperature powder X-ray diffractometric techniques to study frozen and freeze-dried pharmaceutical systems. He is a consultant to numerous pharmaceutical companies and has served as a member of the USP Expert Committee (Excipients test methods). He is a fellow of the AAPS and is the past-chair of the Teachers of Pharmaceutics Section of the American Association of Colleges of Pharmacy. He is a member of the Academy of Distinguished Teachers at the University of Minnesota and is the recipient of the Outstanding Educator Award from AAPS recognizing excellence in education in the technologies related to pharmaceuti-cals. He received the AAPS David J.W. Grant Research Achievement Award in Physical Pharmacy and the PhRMA (Pharmaceutical Research and Manufacturers of America) Foundation Award in recognition of his contributions to pharmaceutics.

11


symposium

SPEAKERSDr. Raman Venkataramanan PhD’79

Raman Venkataramanan is a professor of Pharmaceutical Sciences and Pathology in the University of Pittsburgh and member of Thomas E. Starzl Transplantation Institute, Center for Clinical Pharmacology, University of Pittsburgh Cancer Institute, McGowan Institute for Regenerative Medicine, and Magee-Womens Research Institute. He is the director of clinical pharmacokinetics (PK) laboratory and therapeutic drug monitor-ing program at the university. Venkataramanan received his pharmacy degree from the University of Madras, India; master of pharmacy from the Birla Institute of Technology and Science, India; and doctorate from the University of British Columbia. After a postdoctoral fellowship at the University of Washington, he joined the University of Pittsburgh in 1980. He has been appointed as a Food and Drug Administration special government employee by the Center for Drug Evaluation and Research. He has been a scientific reviewer for the National Center for Complementary and Alternative Medicine, the National Institutes of Health, the National Institute of Child Health and Development, and Medical Research Council, Canada. Venkataramanan serves as a scientific reviewer for several journals. He is an editorial board member for Therapeutic Drug Monitoring, the Journal of Clinical Pharmacology, and two online journals. He is the editor for the American Journal of Analytical Chemistry.

Venkataramanan is very passionate about teaching. He teaches biopharmaceutics and PK courses in the professional pharmacy program, and advanced PK, topics in bio-pharmaceutics, and “Teach Me to Teach You” (art and science of teaching) courses in the graduate program. He has been the primary advisor for 35 graduate students, 60 undergraduate students and 23 postdoctoral fellows. He is the recipient of the Tyler Prize for Stimulation of Research (American Pharmacists Association [APhA], 2011), the Bristol-Meyers Squibb Mentorship in Clinical Pharmacology (American College of Clinical Pharmacy [ACCP], 2009); the Provost’s Award for Excellence in Graduate Education (University of Pittsburgh, 2009); the Innovations in Teaching Award (Rho Chi Society at the University of Pittsburgh, 2009); and the Scholarly Contributions Award (Rho Chi Society at the University of Pittsburgh, 2007).

12


symposium

SPEAKERSDr. Raman Venkataramanan PhD’79

Venkataramanan’s laboratory is involved in optimizing drug therapy through a thorough understanding of the PK and pharmacodynamics (PD) of various medications in patients. The research in his laboratory revolves around “LIFE”. One half addresses “prevention of preterm labour—giving life for the first time” by optimizing the use of 17-hydroxypro-gesterone caproate during pregnancy; the second half addresses “optimization of use of medications in organ transplant patients—a second chance in life”. He has presented more than 130 lectures/seminars at national/international meetings and published over 300 articles. He has been an active member in American Association for Pharmaceutical Scientists (AAPS), American College of Clinical Pharmacology (ACCP), American Association of Colleges of Pharmacy (AACP), American Association for Clinical Chemistry, APhA, International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and American Society of Transplantation (AST). In AAPS, he chaired the Drug Metabolism focus group and the PK, PD, and Drug Metabolism section, and is currently a past member of the AAPS Executive Committee. Venkataramanan has been a member of several committees (nomination, publication, fellow selection, content advisory, SPOD, MSOC) and task forces (education, NIH) within AAPS.

13


symposium

SPEAKERSDr. Diana Chow PhD’81

Diana Shu-Lian Chow, PhD, is professor of pharmaceutics and director of the Institute for Drug Education and Research in College of Pharmacy (located at Texas Medical Center) of the University of Houston. She is also an adjunct professor of Clinical Pharmacology Training Program at Baylor College of Medicine and Texas Children Hospital. She is cur-rently an editor of British Journal of Pharmacology and also serves on the editorial board for the Journal of Drug Development and Industrial Pharmacy.

Dr. Chow earned her MS degree in Natural Product Chemistry from the Ohio State University in 1975, and PhD in Pharmaceutics from UBC in 1981. She has been on the faculty of University of Houston for 33 years.

Professor Chow’s research has focused on translational, preclinical/clinical pharmacoki-netic and pharmacodynamics-guided development of novel drug delivery for anti-cancer, neuroprotective and anti-infective therapies. She has published more than 80 refereed articles, book chapters and technical reports. She has also delivered 188 invited lectures and presentations at national/international conferences and meetings. Her research endeavour has led to an FDA approved product, Busulfan®, in 1999, which is now accepted in use as a standard preparative regimen for blood, marrow and stem trans-plants. Dr. Chow received the Inventor of the Year Award in 2009 from Houston Intellec-tual Property Law Association for clinical merits of the parenteral product of Busulfan®.

Professor Chow’s research has been supported by DoD, NASA, national foundations and major pharmaceutical industries. She has trained 25 PhD, two PharmD/PhD and 7 MS graduates who are all well placed in academia, pharmaceutical industry and FDA.

14


symposium

SPONSORSThank youWe would like to extend our thanks to the following sponsors for their generous support of this event.

NAMED SPEAKERS SPONSORS

PUBLIC PROGRAMMING SPONSORS

University of British ColumbiaFaculty of Pharmaceutical Sciences

2405 Wesbrook Mall, Vancouver, B.C. V6T 1Z3www.pharmacy.ubc.ca

Documents

Agents of Change Research Symposium Program